The WHO recommends parenteral artesunate over quinine and artemether for treating severe Plasmodium falciparum malaria in adults and children. Intravenous administration is preferred. A new one-step, arginine-based formulation eliminates the need for dilution steps, reducing errors and accelerating the initiation of treatment—a critical factor for survival. This formulation was first prequalified by the WHO in 2023. By contrast, the conventional two-step artesunate formulation, which was prequalified in 2010, requires more complex preparation. Clear guidance is essential, as product-specific protocols differ. These training materials aim to support the correct and effective administration of the medication. Accessed on 27/06/2025.